INTRODUCTION
Atopic dermatitis (AD) is an inflammatory skin disease with a chronic, relapsing course. Clinical features of AD vary by age, duration, and severity but can include papules, vesicles, erythema, exudate, xerosis, scaling, and lichenification. However, the most defining and universal symptom of AD is pruritus. Pruritus or itch, defined as an unpleasant urge to scratch, is problematic for many reasons, particularly its negative impact on quality of life. In fact, pruritus in AD can be so severe and unrelenting that it contributes to mental health consequences ranging from hyperactivity [1, 2] to generalized anxiety and even major depressive disorders [3] [4] [5] in some patients.
Despite the profoundly negative impact of pruritus on patients with AD, clinicians and researchers lack standardized and validated methods to objectively measure pruritus [6] . Since pruritus is an internalized sensation, assessment typically hinges on subjective patient reporting. A variety of scales and questionnaires have been developed for this purpose. One of the most commonly used is the Peak Pruritus Numerical Rating Scale (NRS), which consists of a single question for the patient: ''On a scale of 0-10, with 0 being 'no itch' and 10 being 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 h?'' The Peak Pruritus NRS was recently reported to be a well-defined, reliable, sensitive, and valid scale for evaluating worst itch intensity [7] , and its efficient and simple format makes it particularly attractive to busy clinicians.
While such tools can be very useful in clinical practice, patient-reported assessments are less useful for research since biases arise from differences in how an individual experiences and describes pruritus. A ''10 out of 10'' or ''worst itch imaginable'' for one person might be sensed much less severely by another person. For example, a patient with years of chronic itch may experience neural sensitization or desensitization that can skew their self-reporting [8] [9] [10] [11] [12] [13] . Similarly, ''itchy'' is a common way to describe pruritus, but some individuals may experience it as a ''burning'' or a ''tingling'' sensation, potentially resulting in their pruritus being inadequately captured by certain clinical tools.
As these examples show, scales and questionnaires might be helpful for a clinician treating an individual patient with AD, but complementary and more objective tools are needed to rigorously research this condition, such as detecting subtle variations and comparing cohorts before and after an AD treatment or intervention [14, 15] . The purpose of this review is to discuss emerging methods to assess pruritus in AD by describing objective patientcentered tools developed or enhanced over the last decade that can be utilized by clinicians and researchers alike. Examples are provided along with descriptions of how each technology works, instances of use in research or clinical practice, and as applicable, reports of validation studies and correlation with other methods to measure pruritus. Several of these methods measure pruritus indirectly by quantifying scratch, but several new technologies provide novel ways to measure pruritus directly and objectively. Given the centrality of pruritus in AD, there is a need for more tools that allow clinicians and researchers to accurately measure this symptom in individual patients as well as cohorts with AD.
METHODS
This review is based on a literature search in Medline, Embase, and Web of Science databases. The search was performed in February 2019. The following primary keywords were used: ''pruritus,'' ''itch,'' ''atopic dermatitis,'' ''eczema,'' ''measurements,'' ''tools,'' and ''instruments.'' Preliminary results were reviewed, and additional searches were conducted by linking these primary keywords with ''AND'' and ''OR'' statements to the following secondary keywords: ''accelerometer,'' ''wrist actigraphy,'' ''smartwatch,'' ''transducer,'' ''vibration,'' ''brain mapping,'' ''magnetic resonance imaging,'' and ''positron emission tomography.'' These secondary keywords were selected to narrow results to objective methods rather than subjective instruments like scales or questionnaires. When applicable, corresponding Medical Subject Headings (MeSH) were used. Only articles written in English were included, and no restrictions were set on study type. To focus on emerging methods, prioritization was given to results from the last decade (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) (2018) (2019) ). This review is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
RESULTS
The search yielded 49 results in PubMed, 134 results in Embase, and 85 results in Web of Science. Each result was independently reviewed in a standardized manner by two of the authors (M.S., K.L.), and disagreements between reviewers were resolved by consensus. Relevant findings were categorized into the sections that follow, and a summary of these results is presented in Table 1 .
Video Surveillance
Video surveillance is not a new method to assess pruritus in AD, but it is essential to include in this review for two reasons. First, direct observation is considered the gold standard to measure scratching as a proxy for itch. This involves a trainer evaluator watching patients while they sleep and recording the frequency and duration scratching activity in real time [16, 17] . Second, technological advances have made it possible to observe scratching via video surveillance by providing recorded footage that can be reviewed at any time and by multiple evaluators.
In recent years, several advancements have further improved this method of pruritus assessment, making it more efficient and accurate. Video surveillance is almost exclusively used to measure nocturnal itch, when the subject has limited activity. A potential challenge of observing scratching behaviors during sleep is that people are generally under covers that can obscure the camera's view. To address this, infrared video cameras have been employed to capture movements without disturbing sleep [18] . Furthermore, researchers have developed standardized criteria to evaluate recordings. For example, ''scratching bouts'' are typically defined as ''an apparent action of rubbing or scratching to any part of the body with a rhythmical movement using hands, fingers, or feet lasting longer than 5 s'' [19] . By applying this criteria, recordings can be analyzed by multiple people, allowing for a comparison of any difference, and ultimately a determination of a quantitative value for itch. This method is useful in that it offers an objective index of overall scratch activity while simultaneously tracking scratching at specific times and locations [18] .
Despite the advantages of video surveillance, it is a time-consuming endeavor, and patients often decline this method because of privacy concerns [19] . Furthermore, it is possible that the placement of the recording device and/or the patient's body could result in ''blind spots'' where scratching behavior is hidden and therefore not counted (e.g., a person sleeping prone with a scratching hand wedged between their abdomen and the mattress). Another limitation is that patients' awareness of being recorded may alter their normal sleeping behavior, such as reducing the depth or duration of sleep or other conscious or unconscious modifications due to the observation. To 
Acoustic Surveillance
Given the many disadvantages of video surveillance for measuring pruritus in AD, a similar but alternative method has emerged: acoustic surveillance. This method was first tested in an AD mouse model (interleukin-18 transgenic mice) whereby scratching behavior of these mice was captured using a sound recording device [21] . The scratching sounds, including frequency and wavelength information, were analyzed to develop a software program that could recognize and quantify the mice's scratching behavior, similar to video surveillance but with no direct visualization and with automated and thus much faster rates of scratch data analysis. In this mouse model, results from the acoustic counting system were compared to video surveillance and found to be identical [21] . Building upon this promising mouse model, Noro et al. developed a sound detector with similar acoustic surveillance technology but designed to be worn on the wrist of humans and capture their scratching behavior [22] . Very interestingly, this device did not rely on airconducted noises but rather detected the specific bone-conducted sound made by scratching movements through the finger and wrist bones [22] . To test this novel device, sound data were gathered from healthy controls and patients with AD while both groups slept over one 6-h period. The subjects' scratching behavior was simultaneously observed by infrared video. The software took a few minutes to analyze the acoustic data compared to several hours of a human observer scoring video recordings. Ultimately, the authors reported that the scratching time captured by the sound detector was nearly identical to results from video surveillance, the gold standard comparison [22] . Thus, the sound detector eliminated the intrusive need for visualization of human behavior while also rapidly increasing the speed and objectivity of analysis. As with video surveillance, efforts are underway to optimize acoustic surveillance with machine-learning algorithms that analyze sound signals to recognize movement and quantify scratching activity [23] .
While acoustic recording does offer many advantages over video surveillance, this device has only been tested in one small, brief trial as described above. Additional larger, longer-term studies are needed to fully validate this method in a wider variety of patient populations.
Wrist Actigraphy
A wrist actigraph is a portable device that uses a microaccelerator to measure nocturnal wrist movement as a proxy for scratching activity that is correlated to itch in patients with AD [17] . Movement data is collected in two to three planes, stored locally in the device, and seamlessly uploaded for analysis. Although wrist actigraphy has been used for decades [24, 25] recent advancements have improved this technology to be more accurate, precise, and reliable for clinical and research use. Devices are now much smaller and less invasive (e.g., lightweight and wireless), allowing them to be easily used at home with minimal discomfort for the user. In addition, wrist actigraphs are less expensive than before, making this a more affordable options for clinicians and researchers. Furthermore, wrist actigraphy is increasingly being coupled to new methods of analysis to improve usability and accuracy.
Several studies have reported a strong correlation between wrist actigraphy findings and AD disease activity. Studies by Ebata et al. [24] and Benjamin et al. [26] found a high correlation between pruritus scoring from wrist actigraphs and infrared video recordings. However, both studies noted that although wrist actigraphs are sensitive, increased specificity is needed to distinguish nocturnal scratching from other nocturnal movements. A study by Hon et al. [27] evaluated children with AD and determined that wrist actigraphy strongly correlated with disease severity as captured by SCORing Atopic Dermatitis (SCORAD), an instrument that combines objective components of AD (i.e., clinician-assessed signs of pruritus, such as excoriation) with subjective symptoms (i.e., patient-reported itch severity using a visual analogue scale). In this study, wrist activities were correlated with both objective SCORAD components and overall SCORAD values among 24 pediatric patients [27] . Such results support the use of wrist actigraphy as an objective approach to measure pruritus in adult and pediatric AD patient populations.
Despite these advantages, there are several limitations on the use of wrist actigraphy to measure itch. First, wrist actigraphy can only be used to measure nocturnal pruritus, since wrist movement during the day could be due to any number of activities that would be difficult to discriminate from AD-related scratching [28] . Second, actigraphy generally captures itching that involves wrist or arm movement, but depending on placement of the device, it might not record itching with the palm, feet, or slight movements of individual fingers [16] . Furthermore, many patients with AD have developed scratching techniques that involve rubbing their torso or extremities against each other or a part of their bed, which is unlikely to be detected by a device on the wrist. Third, wrist actigraphs are typically placed on the dominant hand only, so any scratching activity from the non-dominant hand would be missed. Fourth, wrists are a very common site for AD involvement, which is unfortunate since wearing an actigraph could potentially cause further irritation to an area of the body already primed for inflammation. A fifth and largely technical point, several studies have validated the use of wrist actigraphy to measure itch in AD, but other results have challenged it. Most notably, a large, multicenter randomized controlled trial among children with AD failed to find a correlation between wrist actigraphy and disease severity or quality of life [29] . This study also found that wrist actigraphy was not responsive to change, an assessment of how an instrument captures changes in disease status, which would limit its utility in randomized controlled trials and other research [29] .
Fortunately, new techniques are being developed to minimize these limitations and optimize wrist actigraphy data for pruritus assessment. Feuerstein et al. evaluated wrist actigraphy data with a clustering analysis designed to differentiate scratching from walking and restless sleep [28] . By including features such as peak frequency and force of movements, the cluster analysis exhibited a high specificity and sensitivity for differentiating walking from restless sleep, demonstrating its ability to distinguish true scratching from other activities [28] . These results were extended by Petersen et al. who incorporated movement features as independent variables in a logistic regression (LR) [30] . This model similarly demonstrated high discriminative ability to separate scratch from other routine movements [30] . Building on this work, Moreau et al. described a two-step approach using high-resolution, three-dimensional wrist actigraphy data: (1) segmenting the data into ''no motion,'' ''single handed motion,'' and ''both handed motion,'' and then (2) discriminating motion segments into scratching and other motion using a bidirectional recurrent neural network (RNN), a type of artificial intelligence that can model dynamic, temporal behavior such as scratching [16] . Results from this approach were compared to infrared video scoring of pruritus among 24 subjects (18 patients with AD and six healthy controls) and demonstrated similar results [16] . The authors also compared their results to the LR by Petersen et al. described above and concluded that the RNN algorithm provided a better estimation of the total amount of scratching and, perhaps more importantly, accurately predicted when scratching occurred [16, 30] . Moreau et al. noted that such capability could be helpful in assessing the effectiveness of a treatment over the course of a night, which is useful data for clinicians managing itch as well as researchers studying medication dosing [16] .
Overall, improvements in the devices themselves and the methods used to analyze the generated data have allowed wrist actigraphy to re-emerge and continuously be improved as a method to assess pruritus in AD. Nevertheless, such methods still must be tested in larger patient populations and directly compared to other tools in large and diverse patient populations in order to be fully validated and suitable for clinical or research use.
Smart Devices
In the last decade, the medical community has leveraged the convenience and computing power of smart devices to learn more about various medical conditions and also deliver novel interventions, such as dietary intake tracking and medication adherence reminders [31, 32] . Pruritus researchers have joined this technological revolution by leveraging the fundamental principles of wrist actigraphy but modernizing it into a smartwatch. In 2015, Lee et al. reported a pilot study in which three subjects wore a smartwatch with an accelerometer to detect scratching. The smartwatch was able to identify scratching behaviors with 98.5-99.0% accuracy for right-hand scratching motion and 93.3-97.6% accuracy for left-hand scratching when compared to infrared video surveillance [33] .
In 2017, a product named Itch Tracker was developed through a partnership between dermatologists, Nestle Skin Health, and Apple Inc. Recognizing the need to have better objective methods to evaluate itch, this team developed a software application (app) that can be installed to broadly used smartwatches and used to measure nocturnal scratching. The app incorporates an algorithm that analyzes acceleration data from the smartwatch and differentiates scratching from other types of movement on the basis of characteristic wrist motion [34] . Furthermore, the app also has a smartphone interface where the user can answer itch-related questionnaires, allowing for subjective, patientreported data to be combined with the objective, smartwatch-detected data.
Itch Tracker was validated in two proof-ofconcept studies, which included a total of 25 patients with AD and 10 healthy controls who were simultaneously evaluated with the app and nocturnal video surveillance. In the first study, the investigators found that there was a statistically significant positive correlation between smartwatch-detected and video-captured scratching time per hour, and the second study demonstrated that total scratching duration in AD patients was significantly longer than in healthy controls and correlated positively with Eczema Area and Severity Index (EASI) scores [35] . The team concluded that the Itch Tracker had high validity and reliability in measuring scratching in AD and conducted a third, larger study with 201 people with similar findings [34] . On the basis of these data, Itch Tracker represents a smart device that can be used to measure scratching and indirectly, but objectively, evaluate the intensity of pruritus among patients with AD. Owing to the simple interface and unobtrusive design of Itch Tracker, it is suitable for widespread use, but further research will be required to validate the app in more diverse patient populations and clinical settings [34] .
Vibration Transducers
Measurement of vibration is another method that is not entirely new but has been updated by modern technologies. In fact, one of the earliest devices to measure itch was called a pruritometer [36] . It consisted of a resistive sensor and amplifier glued to the middle finger of the dominant hand. Fingernail vibration from scratching would induce an electrical signal transmitted to a wristwatch, providing data on the frequency and intensity of scratching [37, 38] . These devices had several limitations, most notably the discomfort of placement in such a conspicuous site and the high likelihood of the device being knocked askew or falling off entirely, thus compromising any data collection.
In recent years, less invasive and more accurate ways to measure itch-related vibration have been developed. In 2017, Kogure and Ebata described the use of a sheet-shaped body vibrometer (SBV) to measure sleep activity among patients with AD [39] . The SBV consists of a sensitive pressure sensor located under a mattress that continuously records any movement or activity [39] . These authors had previously reported the SBV detecting sleep versus wake states with almost identical accuracy to wrist actigraphy in a healthy population [40] . Expanding on this work, the authors compared the SBV to wrist actigraphy in 20 patients with AD and found the SBV to be most useful for overall sleep evaluation in these patients (i.e., amount of motion during sleep) while wrist actigraphy is better suited to specifically evaluate scratching [39] . Therefore, the SBV may not be the best option for measuring pruritus but it is nonetheless another tool in the kit, especially for evaluating the impact of AD on sleep architecture among patients with severe itch.
Neurological Imaging
Neurological imaging has emerged as a particularly novel method to objectively detect functional and anatomical changes in both acute and chronic pruritus. For acute itch, functional magnetic resonance imaging (fMRI) or positron emission tomography (PET) has been used to assess brain activity during experimentally induced itching episodes [41] . In one study, acute histamine-induced itch was compared in eight patients with AD and six healthy controls. PET scanning detected more cerebral activation in patients with AD, including increased activation of the basal ganglia that is known to be a central mediator of the itch-scratch cycle [42] . A similar study using histamine induction with eight AD patients and seven healthy controls utilized arterial spin labeling fMRI and found similar results in terms of significantly higher cerebral perfusion during acute itch among AD patients [43] . In chronic itch, brain imaging studies have shown that scratching induces overactivity in motor-related regions and the cerebral reward circuits. Furthermore, in two studies using arterial spin labeling fMRI to measure brain activity during active scratching, patients with chronic itch were found to have attenuated itch sensation in response to scratching, in addition to significant activation of cerebral structures involved in the central reward system [44, 45] . Taken together, these results demonstrate the pleasurable aspects of scratching to relieve both acute and chronic pruritus and suggest scratching can be addictive for patients with AD.
It is important to note three key limitations of neurological imaging for acute and chronic pruritus associated with AD [41] . First, most of these studies represent small sample sizes and results vary on the basis of itch induction and imaging techniques. Second, no research has been published demonstrating differences in resting state between patients with AD and healthy controls. Instead, these techniques require an external itch stimulus (e.g., histamine-induced) to demonstrate significant differences that might not be exactly the same as in AD-induced itch. Third, methods like fMRI and PET take hours to perform and analyze and are thus inconvenient for patients and quite expensive to the health system. These considerations make brain imaging less practical for use in the clinical setting, especially for routine diagnostics or standard of care.
Despite these limitations, the findings collected from neurological imaging research could help guide future studies towards developing new treatments, including psychological interventions or non-invasive neurological procedures like transcranial direct current stimulation, which targets the pathways involved in the itch-scratch cycle and can have an antipruritic effect in AD [46] . An additional advantage of brain imaging is that it can be used to assess pruritus in AD patients while they are awake, unlikely many of the previously described methods that are limited to nocturnal measurements. For these reasons, it is critical that neurological imaging of pruritus is continued to better understand these pathways and identify potential targets to treat itch in AD [47, 48] .
CONCLUSIONS
The variety of new and improved methods to evaluate pruritus in AD is welcomed by clinicians, researchers, and patients alike. While many of these technologies are promising, no single method discussed in this review can capture the full spectrum of the effects of itch on a patient's quality of life, ranging from the physical consequences like excoriation and lichenification to the mental impacts that can persist even in the absence of pruritus. It is therefore imperative to continue developing methods to quantify itch to accurately evaluate individual patients, guide treatment, and inform research on novel interventions to reduce the symptoms and burdens of itch. Future directions include next-generation smart devices as well as exploring new territories, such as identifying biomarkers that correlate to itch and machine-learning programs to identify itch processing in the brain. As these efforts continue, it will be essential to remain patientcentered by developing techniques that minimize discomfort, respect privacy, and provide accurate data that can be used to better manage itch in AD.
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